Front Page
December 9, 2024
ADAI Lunch & Learn: Pipe Distribution Through a Syringe Services Program to Reduce Higher Risk Drug Consumption (Jan 16, 12pm PT)
Join ADAI and presenter Tom Fitzpatrick, MD (UW Physician & Infectious Diseases Fellow) for our next ADAI Lunch & Learn! In this session, Dr. Fitzpatrick will present interim results from his ADAI Small Grants Project. Heroin, fentanyl, methamphetamine, and cocaine can be injected or smoked. Distributing pipes may encourage people who use drugs (PWUD) to…
December 3, 2024
What’s New in Harm Reduction Research (December 2024)
A review of recently published research on harm reduction topics – December 2024. Need help getting copies of any of these articles? Email Meg Brunner, MLIS (meganw@uw.edu). Free articles have “(open access)” after the titles; all other articles require a subscription to access. Facilitators and barriers to monitoring and evaluation at syringe service programs. (open access)…
November 14, 2024
New from CERP Director Beatriz Carlini: Report & Recommendations of the High Potency Cannabis Think Tank to the State of California
ADAI’s Cannabis Education & Research Program Director Beatriz Carlini, PhD, MPH is one of the co-authors of a new report: “Report and Recommendations of the High Potency Cannabis Think Tank to the State of California.” This report was prepared by a committee of scientists (including Dr. Carlini) and medical experts convened by the California Department…
October 25, 2024
ADAI’s CAAHS is Hiring! NWATTC Project Coordinator & ORN Indigenous Communities Tech Transfer Specialist
ADAI’s Center for Advancing Addiction Health Services (CAAHS) is recruiting for two new positions. Click the links below to find out more about each one and apply! Opioid Response Network Indigenous Communities Technology Transfer Specialist (Req 240043): This position will facilitate access to training, consultation, and guidance resources on evidence-based opioid and stimulant use disorder…
October 16, 2024
ADAI Lunch & Learn Webinar: A Socio-Ecological Approach to Deriving Insights about Stigma Relating to Substance Use (Nov. 14, 12pm PT)
Presenter:Annie Chen, PhDAssociate ProfessorUW Department of Biomedical Informatics and Health Education Stigma relating to substance use disorder can have negative impacts in many aspects of those affected, including but not limited to physical and mental health, employment, housing, social relationships, and reluctance to seek treatment. Despite these consequences, questions remain concerning how stigma occurs, the…
October 14, 2024
2024 ADAI Symposium: Slides & Recordings Available
ADAI hosted a day-long research symposium on September 19, 2024 about “Cannabis, Schizophrenia, and Other Psychotic Disorders,” featuring experts like Marta Di Forti, MD, PhD of King’s College (UK) and Deepak Cyril D’Souza, MD of Yale University. Presentations covered the past, present, and future of cannabis use and psychosis; reviewing the evidence; promising clinical interventions…
September 20, 2024
New ADAI Research: Community-Based Medications First for Opioid Use Disorder
Citation: Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S. Community-based medications first for opioid use disorder – Care utilization and mortality outcomes. Substance Abuse and Rehabilitation 2024;15:173-183. The most effective and evidence-based treatments for opioid use disorder (OUD) are medications for OUD (MOUD) like buprenorphine, methadone, and extended-release injectable naltrexone. However,…
September 18, 2024
ADAI Webinar: Insights into Xylazine and Other Emerging Issues in the Drug Supply in WA (Oct 3, 2pm PT)
This webinar will answer frequently asked questions related to xylazine and other emerging issues in the unregulated drug supply in WA State: Presenters will include Caleb Banta-Green, Ben Biamont, and others from the WA State Community Drug Checking Network, as well as well as representatives from the Public Health-Seattle & King County Street Medicine Team….
September 17, 2024
WA State Drug Brief: BTMPS: New Substance Found in Community Drug Checking Samples
In June 2024, a new substance, Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate (BTMPS), was detected in the unregulated drug supply nationally in community drug testing programs, most commonly in products sold as and containing fentanyl. BTMPS is an industrial chemical with no approved use in humans. The effects of the substance and why it might be in the drug…
September 16, 2024
Results from the PerCH Survey: Report and Webinar Recording
What do permanent supportive housing residents think about drug use, overdose, where they live, and their service needs? Residents living in permanent supportive housing are at a higher risk to witness or have an overdose. To learn more about this group of people and substance use issues, ADAI Research Coordinator and UW MSW student Saul…
Next page